Author(s)

Tanja Gmeiner¹, Jasna Grzelj², Borut Strukelj¹, Luka Stopar³, Pij Bogomir Marko⁴

¹Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
²Krka, d. d., Novo Mesto, Slovenia.
³Institute Jozef Stefan, Ljubljana, Slovenia.
⁴Department of Dermatovenerology, University Medical Centre Maribor, Maribor, Slovenia.

Immense changes have been introduced in psoriasis treatment, including successful systemic treatment of inflammation and education of psoriatic patients. The focus of this review is the latest developments in the understanding of the aetiopathogenesis of psoriasis, the significance of its comorbidities, treatment possibilities and long-term management using the latest insight provided by pharmacogenetics and identification of biomarkers. The successful control of the disease leads to reduction of myocardial infarction and long-term cardiovascular risk but is usually achieved after various therapeutic attempts until the best-matched treatment for the individual is identified. There is a high unmet medical need for revealing biomarkers associated with disease prognosis, comorbidities, response to therapy and adverse effects. More studies have to be performed for identification and validation of biomarkers and implementation of personalized medicine into clinical practice.

Biologicals, Psoriasis, Pharmacotherapy, Dermatology

Gmeiner, T. , Grzelj, J. , Strukelj, B. , Stopar, L. and Marko, P. (2020) Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis. Pharmacology & Pharmacy, 11, 373-401. doi: 10.4236/pp.2020.1112030.